Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2005 Jul 20:(3):CD005451.
doi: 10.1002/14651858.CD005451.

Carbamazepine for acute and chronic pain

P J Wiffen  1 , H J McQuay, R A Moore
Affiliations
Meta-Analysis

Carbamazepine for acute and chronic pain

P J Wiffen et al. Cochrane Database Syst Rev. .

Update in

Abstract

Background: Anticonvulsant drugs have been used in the management of pain since the 1960s. The clinical impression is that they are useful for chronic neuropathic pain, especially when the pain is lancinating or burning.

Objectives: To evaluate the analgesic effectiveness and adverse effects of the anticonvulsant medicine carbamazepine for pain management in clinical practice and to identify a clinical research agenda. Migraine and headache studies are not included in this review.

Search strategy: Randomised trials (RCTs) of anticonvulsants in acute, chronic or cancer pain were identified by MEDLINE (1966-2004), EMBASE (1994-2004), SIGLE (1980-2004) and the Cochrane Controlled Trials Register (CENTRAL/CCTR) (Cochrane Library Issue 3, 2003). In addition, 41 medical journals were hand searched for a previous version of this review. Additional reports were identified from the reference list of the retrieved papers, and by contacting investigators. Date of most recent search: November 2004.

Selection criteria: Randomised trials reporting the analgesic effects of carbamazepine in patients, with subjective pain assessment as either the primary or a secondary outcome.

Data collection and analysis: Data were extracted by two independent reviewers, and trials were quality scored. Numbers-needed-to-treat (NNTs) were calculated from dichotomous data for effectiveness, adverse effects and drug-related study withdrawal, for individual studies and for pooled data.

Main results: Twelve studies were included (404 participants). Four studies included trigeminal neuralgia patients. Two studies which provided evaluable data yielded an NNT for effectiveness of 1.8 (95%CI 1.4-2.8). For diabetic neuropathy there was insufficient data for an NNT to be calculated.Numbers-needed-to-harm (NNHs) were calculated where possible by combining studies for each drug entity irrespective of the condition treated. The results were, for minor harm, carbamazepine 3.7 (CI 2.4-7.8), NNHs for major harm were not statistically significant for carbamazepine compared with placebo. There is no evidence that carbamazepine is effective for acute pain.

Authors' conclusions: There is evidence to show that carbamazepine is effective but trials are small.

PubMed Disclaimer

LinkOut - more resources